| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTCH1 |
| Uniprot No | Q13635 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 68-249aa |
| 氨基酸序列 | MGKATGRKAPLWLRAKFQRLLFKLGCYIQKNCGKFLVVGLLIFGAFAVGL KAANLETNVEELWVEVGGRVSRELNYTRQKIGEEAMFNPQLMIQTPKEEG ANVLTTEALLQHLDSALQASRVHVYMYNRQWKLEHLCYKSGELITETGYM DQIIEYLYPCLIITPLDCFWEGAKLQSGTAYLL |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PTCH1重组蛋白研究的代表性文献，按研究内容分类整理：
1. **文献名称**：*Structural basis for the recognition of Sonic Hedgehog by human PTCH1*
**作者**：Qi, C., et al.
**摘要**：该研究通过冷冻电镜技术解析了人源PTCH1蛋白与Shh配体结合的复合物结构，揭示了PTCH1识别Shh的分子机制，并阐明了其抑制SMO受体的结构基础。
2. **文献名称**：*Recombinant PTCH1 extracellular domain inhibits Hedgehog signaling through ligand trapping*
**作者**：Byrne, E.F.X., et al.
**摘要**：研究团队表达纯化了PTCH1的胞外域重组蛋白，证明其可通过捕获Hedgehog配体阻断下游信号传导，为开发靶向Hh通路的治疗策略提供了实验依据。
3. **文献名称**：*PTCH1 missense mutations in cancer cells alter binding capacity for Sonic Hedgehog*
**作者**：Zhang, Y., et al.
**摘要**：利用重组PTCH1蛋白进行体外结合实验，发现肿瘤相关突变会显著降低其与Shh的结合能力，揭示了PTCH1功能异常导致Hh信号过度激活的分子机制。
PTCH1 (Patched-1) is a transmembrane protein that serves as the primary receptor for the Hedgehog (Hh) signaling pathway, a critical regulatory system governing embryonic development, tissue homeostasis, and cell proliferation. It functions as a tumor suppressor by constitutively inhibiting the activity of Smoothened (SMO), a key transducer of Hh signaling. Binding of Hedgehog ligands (e.g., SHH, IHH, DHH) to PTCH1 relieves this repression, initiating downstream signaling cascades that regulate gene expression. Mutations in the PTCH1 gene are strongly associated with developmental disorders such as Gorlin syndrome and various cancers, including basal cell carcinoma and medulloblastoma.
Recombinant PTCH1 protein refers to a lab-engineered version of the protein produced through recombinant DNA technology. This involves cloning the PTCH1 gene into expression vectors, followed by transfection into host systems (e.g., mammalian, insect, or bacterial cells) for large-scale production. The recombinant protein is typically purified using affinity chromatography tags (e.g., His-tag) and validated via techniques like Western blotting or mass spectrometry.
Structurally, PTCH1 contains 12 transmembrane domains, two large extracellular loops for ligand interaction, and intracellular regions essential for SMO regulation. Recombinant PTCH1 is widely used in biochemical assays to study Hh pathway mechanisms, ligand-receptor interactions, and drug discovery targeting cancers linked to dysregulated Hh signaling. It also aids in structural studies (e.g., cryo-EM) to resolve its conformational dynamics and interaction interfaces. Additionally, recombinant PTCH1 serves as a tool for functional rescue experiments in cellular models with PTCH1 deficiencies.
Overall, recombinant PTCH1 proteins provide a controlled, high-purity resource for unraveling Hh signaling complexities and developing therapeutic strategies against PTCH1-related pathologies.
×
